ANZCTR search results

Purpose of the Study This study seeks to evaluate the effect of a slowly increasing or decreasing doses of PBMt (number of sessions per week) on the signs and symptoms of Parkinson’s disease whilst participants may also be receiving usual care physiotherapy. The doses will be slowly altered each four weeks and there will be four dose variations evaluated. We will measure the effects of the treatments in two ways throughout this period: a) at home by observations made by the chosen significant other/carer b) in the clinical setting with specialist and physiotherapy evaluations. Also, there will be two different forms of medical light trialled: a) one that could eventually be recommended for home use, and b) one that is a clinic based therapy. In this study, the medical light will be applied by a trained physiotherapist to the head (in Brisbane arm of trial) or other parts of the body (spine and abdomen in Sydney arm of trial), and in combination (head, spine and abdomen) in the Adelaide arm. In the Brisbane, participants will be randomly allocated into receiving one of two forms of light device. In the Sydney arm of the trial, only one device will be trialled and evaluation of the gut microbiome will be added to the outcome measures. In the Adelaide arm, the two devices will be used and the gut microbiome will be analysed as well.

Background: Depression is at least three times more common in people with coronary heart disease (CHD) but is underdiagnosed and inadequately treated. Psychological treatments are preferred by most patients with depression but are complex and costly to deliver. Behavioural activation (BA) is a simpler alternative that could potentially be delivered by therapists (physio, occupational) as an add on to cardiac rehabilitation. Objective: To determine the feasibility of providing therapist delivered BA as an adjunct to cardiac rehabilitation to patients with depression and coronary heart disease. Design: Feasibility – before and after – trial. Methods: Patients referred to the North East Rehabilitation Center for cardiac rehabilitation program will be screened for depression using the PHQ-2. Those with a score >3 (indicative of at least mild depression) will be invited to take part in the study. Patients already receiving depression treatment (either medication or psychological), who are alcohol or drug dependent, are suicidal, have cognitive impairment or psychosis will be excluded from the trial. Key outcomes: 1. To determine the number of patients we need to ask to participate in the trial to get one to consent, 2. Proportion of patients who complete treatment (and the number of sessions they attend), 3. Completion of outcome measures, 4. Acceptability of behavioral activation as part of cardiac rehabilitation, 5. Proportion of patients that complete the trial. Unexpected harms associated with combining behavioral activation and cardiac rehabilitation will be closely monitored. Discussion: This study will provide evidence on the feasibility of conducting a trial to evaluate the efficacy of incorporating behavioral activation as part of routine cardiac rehabilitation for depressed patients with coronary heart disease.

To compare the feasibility, acceptability and impact of installing sit-stand workstations plus advice, with or without exercise, on back pain and sitting time in office workers at risk of low back pain.

The research project aimed to compare body composition and maximal strength and power performance in Powerlifting and Olympic Weightlifting exercises in the same group of resistance-trained participants exposed to 3-months ketogenic diet and 3-months of usual control diet.

FT011 is being investigated as a potential drug to inhibit scar formation in the eye after surgery. The main aim of this study is to assess whether FT011 can enter the eye, as well as determine the safety of FT011 in the eye.

This study seeks to establish a reference range for a urinary kryptopyrrole test produced and conducted by SAFE Analytical Laboratories Pty Ltd ("the test"), This study is aiming to provide suitable data to enable registration of the test on the Australian Register of Therapeutic Goods (ARTG). Four parts to this study have been designed to correlate the urinary kryptopyrrole levels with health and disease states as observed in adult populations.

The aim of this study is to assess the efficacy of Trigonella foenum-graecum (Fenugreek) Seed Extract and Coccinia indica in reducing elevated normal blood glucose levels through reducing insulin levels (B-cell function) and reducing insulin resistance (blood glucose) in pre-diabetics. In addition, other parameters associated with altered metabolism that contribute to the development of diabetes, HBa1c, lipid studies, body weight will also be assessed.

The aim of the study is to use of an intranasal spray containing of IND02 (standardized hydroalcoholic extract of Cinnamonum zeylanicum bark extract) to determine if it is superior to placebo in reducing the severity of the symptoms of seasonal allergic rhinitis (SAR) over 7 days.

This study aims to improve the translation of research evidence into healthcare practice. We will achieve this aim by comparing two different strategies to help allied health managers make resource allocation decisions in the hospital setting. One group will be provided with an "evidence-based policy recommendation" document; the other group will be provided with the same document with the addition of an expert knowledge broker to assist in the decision-making process; A third "control" group will not be provided with either of the interventions during the study period. The success of these research implementation strategies will be measured by comparing between group changes in practice to align with the policy recommendations. We will also explore the (1) opportunity cost to make decision (time to make decision, resources used, and knowledge broker time attributable to each participant in implementation strategy group 2); (2) participant perceptions of the research evidence related to this issue; (3) sources of evidence relied upon during decision-making; (4) domains of decision making that were most influential upon the decision to adopt the policy or not; (5) average hospital length of stay at baseline and 12-months; and (6) suggested improvements, perception of risk, and barriers and facilitators encountered in adopting or not adopting the policy recommendation.

The purpose of this study is to test the safety, tolerability and anti-tumour activity of the research study drug, guadecitabine. Who is it for? You may be eligible for this study if you are an adult who has been diagnosed with T-cell non-Hodgkin lymphoma, which has (a) not been treated, (b) been deemed unsuitable for standard therapy or (c) have relapsed or refractory disease. Study details All participants will receive subcutaneous injections of guadecitabine for the first 5 days of a 28 day treatment cycle. Treatments will be given for at least 6 of these 28 day cycles. This is a safety and efficacy trial, so any adverse events will be recorded and the effect of the study treatment on the lymphoma will be monitored using a PET or CT scan. This study will provide information about this study drug and allow subsequent study of this potential treatment for T-cell non-Hodgkin lymphoma.